<SEC-DOCUMENT>0001193125-19-100905.txt : 20190409
<SEC-HEADER>0001193125-19-100905.hdr.sgml : 20190409
<ACCEPTANCE-DATETIME>20190408190402
ACCESSION NUMBER:		0001193125-19-100905
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190408
FILED AS OF DATE:		20190409
DATE AS OF CHANGE:		20190408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		19738250

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d581756d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of April 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36697</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">177-181</FONT> avenue Pierre Brossolette </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;&nbsp;Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated April&nbsp;8, 2019.</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;8, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Schilansky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Schilansky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Deputy Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g581756g23g81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Announces Closing of Global Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (the &#147;Company&#148;) (Euronext: DBV &#150; ISIN: FR0010417345 &#150; Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical
company, today announced the settlement and delivery of an underwritten global offering of an aggregate of 6,000,000 ordinary shares reserved to specified categories of investors in (i)&nbsp;an offering of 2,447,500 ordinary shares in the form of
4,895,000 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe, at an offering price of $6.75 per ADS (on the basis of an exchange rate of $1.1233 = &#128;1.00), and (ii)&nbsp;a private placement
of 3,552,500 ordinary shares in Europe (including France), at an offering price of &#128;12.02 per ordinary share. The number of ordinary shares (including in the form of ADSs) sold in the global offering reflect the exercise in full of the
underwriters&#146; option to purchase additional ordinary shares (including in the form of ADSs). The total gross proceeds from the global offering, including from the exercise of the underwriters&#146; option to purchase additional ordinary shares
(including in the form of ADSs), were approximately $81.0&nbsp;million (&#128;72.1 million), before deducting commissions and estimated offering expenses. Each ADS represents the right to receive <FONT STYLE="white-space:nowrap">one-half</FONT> of
one ordinary share. The ADSs are listed on the Nasdaq Global Select Market under the symbol&nbsp;&#147;DBVT&#148;, and the Company&#146;s ordinary shares are listed on Euronext Paris under the symbol &#147;DBV&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC and Citigroup acted as joint lead book-running managers for the global offering. H.C. Wainwright&nbsp;&amp; Co. acted as lead
manager for the global offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to use the net proceeds from the global offering, together with its existing cash and cash
equivalents, to fund the development and, if approved, prepare for the commercialization of Viaskin Peanut, to advance development of the Company&#146;s other product candidates and for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3,</FONT> as amended, relating to the securities to be issued in the global offering
was filed with the Securities and Exchange Commission and initially became automatically effective on July&nbsp;27, 2016. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration
statement. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the Securities and Exchange Commission and is available on the Securities and Exchange Commission&#146;s website
at <U>www.sec.gov</U>. Copies of the final prospectus supplement and accompanying prospectus may also be obtained for free from: Goldman Sachs&nbsp;&amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-471-2526,</FONT></FONT></FONT> facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-902-9316</FONT></FONT> or via email:
<U><FONT STYLE="white-space:nowrap">prospectusgroup-ny@ny.email.gs.com</FONT></U>; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or via telephone: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">800-831-9146.</FONT></FONT> No prospectus subject to approval by the French Autorit&eacute; des March&eacute;s Financiers (AMF) has been filed in France in connection with the global offering. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g581756g29b07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;* </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies
is developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT&reg;, DBV&#146;s method of
delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and <FONT STYLE="white-space:nowrap">non-invasive</FONT> product candidates, the Company is dedicated to safely transforming
the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a
human <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and
other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, Summit, NJ and New York, NY. The Company&#146;s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code:
FR0010417345), part of the SBF120 index, and the Company&#146;s ADSs (each representing <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, including statements about the anticipated use of proceeds from the offering. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Factors that could cause
actual results to differ materially from those described or projected herein include risk associated with market and other financing conditions, risks associated with clinical trials and regulatory reviews and approvals, and risk related to the
sufficiency of the Company&#146;s existing cash resources and liquidity. A further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des
March&eacute;s Financiers and U.S. Securities and Exchange Commission, including in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise forward-looking statements as a result of new information, future events
or circumstances, or otherwise, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Investor Relations Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sara Blum Sherman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations&nbsp;&amp;
Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;212-271-0740</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">sara.sherman@dbv-technologies.com</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joe Becker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Global Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-646-650-3912</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT
STYLE="white-space:nowrap">joseph.becker@dbv-technologies.com</FONT></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are
required to inform themselves about and to observe any such potential local restrictions. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g581756g29b07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No prospectus subject to approval by the French Autorit&eacute; des March&eacute;s Financiers (AMF) has been
filed in connection with the global offering. Copies of the Company&#146;s Reference Document, including the risk factors, registered by the AMF on April&nbsp;1, 2019, under No. <FONT STYLE="white-space:nowrap">D.19-0235</FONT> are available for
free at the Company&#146;s head office located at: <FONT STYLE="white-space:nowrap">177-,181</FONT> avenue Pierre Brossolette, 92120 Montrouge, France, and on the AMF&#146;s website at
<U><FONT STYLE="white-space:nowrap">www.amf-france.org</FONT></U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document does not constitute an offer to the public in France and the securities
referred to in this document can only be offered or sold in France pursuant to article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">411-2-II</FONT></FONT> of the French Monetary and Financial Code to (i)&nbsp;providers of
third party portfolio management investment services, (ii)&nbsp;qualified investors (investisseurs qualifi&eacute;s) acting for their own account and/or (iii)&nbsp;a limited group of investors (cercle restreint d&#146;investisseurs) acting for their
own account, all as defined in and in accordance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D. <FONT STYLE="white-space:nowrap">411-1</FONT> to D. <FONT
STYLE="white-space:nowrap">411-4</FONT> and D. <FONT STYLE="white-space:nowrap">754-1</FONT> and D. <FONT STYLE="white-space:nowrap">764-1</FONT> of the French Monetary and Financial Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement is not an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of
4&nbsp;November 2003, as amended (the &#147;Prospectus Directive&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the member States of the European Economic Area, no action has
been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any
relevant member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the
Prospectus Directive and/or to applicable regulations of that relevant member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is only being distributed to, and is only directed at,
persons in the United Kingdom that (i)&nbsp;are &#147;investment professionals&#148; falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Order&#148;), (ii) are persons
falling within Article 49(2)(a) to (d) (&#147;high net worth companies, unincorporated associations, etc.&#148;) of the Order, or (iii)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of
Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;Relevant
Persons&#148;). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant
Persons and will be engaged in only with Relevant Persons. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g581756g23g81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g581756g23g81.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M=VC^(>QR[O+\ _X49/\ \_(_[^__ &-'UC'=H_B'L<N[R_ /^%&3_P#/R/\
MO[_]C1]8QW:/XA['+N\OP#_A1D__ #\C_O[_ /8T?6,=VC^(>QR[O+\ _P"%
M&3_\_(_[^_\ V-'UC'=H_B'L<N[R_ /^%&3_ //R/^_O_P!C1]8QW:/XA['+
MN\OP#_A1D_\ S\C_ +^__8T?6,=VC^(>QR[O+\ _X49/_P _(_[^_P#V-'UC
M'=H_B'L<N[R_ /\ A1D__/R/^_O_ -C1]8QW:/XA['+N\OP#_A1D_P#S\C_O
M[_\ 8T?6,=VC^(>QR[O+\ _X49/_ ,_(_P"_O_V-'UC'=H_B'L<N[R_ /^%&
M3_\ /R/^_O\ ]C1]8QW:/XA['+N\OP#_ (49/_S\C_O[_P#8T?6,=VC^(>QR
M[O+\ _X49/\ \_(_[^__ &-'UC'=H_B'L<N[R_ /^%&3_P#/R/\ O[_]C1]8
MQW:/XA['+N\OP#_A1D__ #\C_O[_ /8T?6,=VC^(>QR[O+\ _P"%&3_\_(_[
M^_\ V-'UC'=H_B'L<N[R_ /^%&3_ //R/^_O_P!C1]8QW:/XA['+N\OP#_A1
MD_\ S\C_ +^__8T?6,=VC^(>QR[O+\ _X49/_P _(_[^_P#V-'UC'=H_B'L<
MN[R_ /\ A1D__/R/^_O_ -C1]8QW:/XA['+N\OP#_A1D_P#S\C_O[_\ 8T?6
M,=VC^(>QR[O+\ _X49/_ ,_(_P"_O_V-'UC'=H_B'L<N[R_ /^%&3_\ /R/^
M_O\ ]C1]8QW:/XA['+N\OP#_ (49/_S\C_O[_P#8T?6,=VC^(>QR[O+\ _X4
M9/\ \_(_[^__ &-'UC'=H_B'L<N[R_ /^%&3_P#/R/\ O[_]C1]8QW:/XA['
M+N\OP#_A1D__ #\C_O[_ /8T?6,=VC^(>QR[O+\ _P"%&3_\_(_[^_\ V-'U
MC'=H_B'L<N[R_ /^%&3_ //R/^_O_P!C1]8QW:/XA['+N\OP#_A1D_\ S\C_
M +^__8T?6,=VC^(>QR[O+\ _X49/_P _(_[^_P#V-'UC'=H_B'L<N[R_ /\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H JRZC90-MDNHE/H7
M&::BV*Z0^&\M;CB&XC<^BL":&F@33)Z0PH * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H CGGCMH7FE;:BC)--*^B!NQC$7&J1FXNIC:6 Y" X+#U)K32.
MBW,]7J]B&.;24^6UTM[D#C>(MWZFG:75A>/1 6T:X<1S6KV,AZ$KL_EQ^='O
M+;4/=>Y96XN=(D1+J0SV3G"S=T^M392VW'=QW-H$$ @Y%9EA0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * ,2!BMSK<P^^HP/P4UH]D
MB%U+FBHJ:/;;1C*Y/U-3/XF..Q?J2@H RM;^3[#*O#K<J!]#UJX=41+H$?R>
M)I@.CVX8_7.*/L!]HU:@L* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* ,O7?$.E^&K)+S5KK[- [B-6V,V6()Q@ ]@:J,7+1";2W,*+XJ>"I9%C76T
M!)P"T4BC\RN!5>RGV)YXG6P3Q7,"3P2I+%(-R.AR&'J#6>Q9)0 4 % !0 4
M% &/K_BC1_#$4,NL7GV9)F*QG8S9(Z_=!JHQ<MA.2CN8]O\ %+P7<S+$FN1J
MS' ,D;H/S(P*KV4UT)YXG7(Z21K)&P9&&593D$>HK,L=0!S?B+QKIOAG5=.T
MZ\BG>:_;;$8U! ^8#G)]ZN,')71+DD['25!04 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!C:OH9NYEO[&7[+J47W9!T
M<>C>HK:G5Y5RRU1RUL/SOG@[27]:F6^JVDTBVVOV[:??)PLPX5O<-_C6GLWO
M3=T91Q*3Y:ZY7^!HPI=;0;36XIHNV[#?KS63MUB=2DG\,B*YQ&I;4]>1(O[B
M$+G_ !_*G%-_#$F52$5><BG%>S7Z&R\-VQ@MSQ)>R+@#_=SR36G(H:U7\CE]
MM.M[M!67?_(WM)TBVTBV,4 +.QS)*W+.?4FL9U'-W9UT:,:,;1+]9FP4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT'=CGCH::B[7%>SL;%2,* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV0V]F&_A@0XX^I'Z&BI[J4 AJW(]!K$T"@ H * "@ H * "@ H * "@ H *
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M  "P!ZX&.?UI**LF-S:;5^PWSKM0B>8W[V4JC2 (0H''\/!/N*=HAS36G?\
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M$C1(9!T8J,C\:+O87*F[V')%'&6*(JECEB!C)]Z+L:26PZD,* "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "8 .<<T
M +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
) !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g581756g29b07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g581756g29b07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&
M!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8#
M P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# S_P  1" "C Q8# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MH CD/!_X#_6BB0\'_@/]:*"9;_<24444%!1110 4444 %%%% !1110 4444
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M"+X;_P# >C_AC7X6?]"+X;_\!Z/]9N(?^?-#[ZG_ ,B']A\+?\_,1_X#3_\
MDS^2;_A1'CC_ *$_Q'_X+I:/^%$>./\ H3_$?_@NEK^MG_AC7X6?]"+X;_\
M >C_ (8U^%G_ $(OAO\ \!Z/]9N(?^?-#[ZG_P B']A\+?\ /S$?^ T__DS^
M2;_A1'CC_H3_ !'_ ."Z6C_A1'CC_H3_ !'_ ."Z6OZV?^&-?A9_T(OAO_P'
MH_X8U^%G_0B^&_\ P'H_UFXA_P"?-#[ZG_R(?V'PM_S\Q'_@-/\ ^3/Y)O\
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M ."Z6C_A1'CC_H3_ !'_ ."Z6OZV?^&-?A9_T(OAO_P'H_X8U^%G_0B^&_\
MP'H_UFXA_P"?-#[ZG_R(?V'PM_S\Q'_@-/\ ^3/Y)O\ A1'CC_H3_$?_ (+I
M:/\ A1'CC_H3_$?_ (+I:_K9_P"&-?A9_P!"+X;_ / >C_AC7X6?]"+X;_\
M >C_ %FXA_Y\T/OJ?_(A_8?"W_/S$?\ @-/_ .3/Y)O^%$>./^A/\1_^"Z6C
M_A1'CC_H3_$?_@NEK^MG_AC7X6?]"+X;_P# >C_AC7X6?]"+X;_\!Z/]9N(?
M^?-#[ZG_ ,B']A\+?\_,1_X#3_\ DS^2;_A1'CC_ *$_Q'_X+I:/^%$>./\
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M7X6?]"+X;_\  >C_ (8U^%G_ $(OAO\ \!Z/]9N(?^?-#[ZG_P B']A\+?\
M/S$?^ T__DS^2;_A1'CC_H3_ !'_ ."Z6C_A1'CC_H3_ !'_ ."Z6OZV?^&-
M?A9_T(OAO_P'H_X8U^%G_0B^&_\ P'H_UFXA_P"?-#[ZG_R(?V'PM_S\Q'_@
M-/\ ^3/Y)O\ A1'CC_H3_$?_ (+I:/\ A1'CC_H3_$?_ (+I:_K9_P"&-?A9
M_P!"+X;_ / >C_AC7X6?]"+X;_\  >C_ %FXA_Y\T/OJ?_(A_8?"W_/S$?\
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M+I:/^%$>./\ H3_$?_@NEK^MG_AC7X6?]"+X;_\  >C_ (8U^%G_ $(OAO\
M\!Z/]9N(?^?-#[ZG_P B']A\+?\ /S$?^ T__DS^2;_A1'CC_H3_ !'_ ."Z
M6C_A1'CC_H3_ !'_ ."Z6OZV?^&-?A9_T(OAO_P'H_X8U^%G_0B^&_\ P'H_
MUFXA_P"?-#[ZG_R(?V'PM_S\Q'_@-/\ ^3/Y)O\ A1'CC_H3_$?_ (+I:/\
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MT(OAO_P'H_X8U^%G_0B^&_\ P'H_UFXA_P"?-#[ZG_R(?V'PM_S\Q'_@-/\
M^3/Y)8_V>_'<[;5\'>(MXR0/L4D:*I)P!17]:;?L7_"NY.V7P'X;D&%SFV!)
M(  /Y45M'BC/;>]2H_*4[?\ I)4<IX8BK>WQ"_[=I_\ R9ZS1116!Y84444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T?
MZS_/M10/]9_GVHH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D!1110 4444 %%%% !1110 4444 %%%% !1110 8YHHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
